Global trends in the distribution of Candida species causing candidemia
|
|
- Barry Peters
- 6 years ago
- Views:
Transcription
1 REVIEW / Global trends in the distribution of Candida species causing candidemia J. Guinea 1,2,3,4 1) Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Mara~non, Universidad Complutense de Madrid, Madrid, Spain, 2) Instituto de Investigacion Sanitaria Gregorio Mara~non, Madrid, Spain, 3) CIBER de Enfermedades Respiratorias (CIBER RES CB06/06/0058), Madrid, Spain and 4) Medicine Department, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain Abstract Only five species account for 92% of cases of candidemia (Candida albicans, C. glabrata, C. tropicalis, C. parapsilosis, and C. krusei); however, their distribution varies in population-based studies conducted in different geographical areas. C. albicans is the most frequent species, but considerable differences are found between the number of cases caused by C. glabrata and C. parapsilosis. Studies from Northern Europe and the USA reported a high number of cases caused by C. glabrata, whereas studies from Spain and Brazil demonstrated a lower number of cases caused by C. glabrata and a higher number of cases attributed to C. parapsilosis. Globally, the frequency of C. albicans is decreasing, while that of C. glabrata and C. krusei is stable, and C. parapsilosis and C. tropicalis are increasing. Patient characteristics and prior antifungal therapy also have a considerable influence on the distribution and frequency of Candida spp., regardless of the geographical area. C. albicans is more frequent in patients aged up to 18 years, the frequency of C. parapsilosis decreases with age, and C. glabrata is more common in the elderly. Finally, the presence of horizontal transmission of Candida spp. isolates (reported mainly in patients from the adult medical and post-surgical ICU, patients from oncology haematology units, and neonates) can affect species distribution. Keywords: C. albicans, C. glabrata, C. parapsilosis, candidemia, invasive candidiasis, outbreaks, population-based, species distribution Article published online: 10 February 2014 Clin Microbiol Infect 2014; 20 (Suppl. 6): 5 10 Corresponding author: J. Guinea, Servicio de Microbiologıa Clınica y Enfermedades Infecciosas-VIH, Hospital General Universitario Gregorio Mara~non, C/Dr. Esquerdo 46, Madrid, Spain jguineaortega@yahoo.es Background Fungal infections have become a major problem in hospitals, and the number of episodes of sepsis caused by fungi has been increasing since the early 1990s [1,2]. Candida spp. remains the most common cause of invasive fungal infections [3 5], and the incidence of candidemia, which is estimated at 72.8 cases per million inhabitants and year, clearly exceeds that of invasive aspergillosis and mucormycosis [6]. Candidemia is a consequence of advances in health care. During the last 20 years, we have observed an improvement in diagnostic procedures, the development and commercialization of new antifungal agents, and the implementation of strategies to prevent candidemia; nevertheless, the incidence of candidemia has increased [7]. Candidemia is generally diagnosed using blood cultures, although diagnosis remains a challenge for clinicians and microbiologists; in fact, half of all cases of invasive Candida infections go undetected in blood cultures [8]. Given these limitations, the true epidemiology and incidence of invasive candidiasis is imprecise. The incidence of candidemia expressed as cases per inhabitants has been reported to range from 1 to 8 cases [4]; in a study carried out in Brazil, incidence reported as cases per admissions was higher (249 cases per admissions) [9]. In a recent 1-year population-based study conducted in Spain (29 hospitals, 773 cases), the incidence of candidemia was 8.1 cases per inhabitants, which is similar to that reported in other European studies [10]. Candidemia has an attributable mortality of 15 35% for adults and 10 15% for neonates, and the hospitalization cost for each episode is approximately US$ [11 13]. The rates of Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases
2 6 Clinical Microbiology and Infection, Volume 20 Supplement 6, June 2014 CMI early and late mortality (7 days and 30 days after diagnosis, respectively) are different (13% vs. 30%). Whereas early mortality is associated with factors such as appropriate antifungal therapy and early removal of central venous catheters, late mortality is associated with factors related to the baseline condition of the host [10]. The mortality rate is clearly correlated with a delay in the initiation of appropriate antifungal treatment [14,15]. Incorrect treatment includes absence of antifungal treatment, a delay in initiation, or the use of an inactive agent. Therefore, efforts to minimize these three situations should help to reduce the mortality of candidemia. Knowledge of the frequency of causative species would facilitate appropriate selection of empirical antifungal treatment. The distribution of Candida spp. causing candidemia varies in population-based studies carried out in different geographical areas. Furthermore, notable differences can also be observed between hospital units. However, the frequency of Candida species causing candidemia is also dependent on the predisposing conditions of the patients infected, the antifungal agents they receive, and the local hospital-related factors. This review discusses global trends in the distribution of Candida spp. by looking at three main areas: influence of the geographic area, influence of predisposing conditions of the patients, and influence of local hospital epidemiology. Influence of the Geographical Area The list of Candida species causing candidemia is long and continues to expand as a consequence of more precise identification. The ARTEMIS DISK Global Antifungal Surveillance Study includes a large registry of invasive Candida isolates collected from 127 medical centers worldwide (39 countries). Data from this registry showed that only five species (C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, and C. krusei) accounted for 92% of cases of candidemia [16]. C. albicans was the most common cause of candidemia worldwide, accounting for 62% of cases [7,16]. However, the ranking of the abovementioned top 5 species is variable. Fig. 1 summarizes the proportion of cases 100% 90% 80% 70% 60% 50% C. albicans C. glabrata C. parapsilosis C. tropicalis C. krusei Other ,00 10, , % 30% 20% % 0% Iceland 2002 [18] Iceland 2013 [26] Finland 2003 [19] Norway 2006 [24] Denmark 2005 [22] Denmark 2011 [23] USA 1999 [17] USA 2004 [20] USA 2012 [25] Spain 2005 [21] Spain 2013 [10] FIG. 1. Proportion of the most relevant Candida species from population-based studies reporting on candidemia in different countries.
3 CMI Guinea Global trends in Candida species distribution 7 of candidemia involving the most relevant Candida species from population-based studies conducted in different countries [10,17 26]. C. albicans was the main cause of candidemia in all of them. However, considerable differences were found in the proportion of cases caused by C. glabrata and C. parapsilosis. This finding has an important clinical impact, as these species show diminished susceptibility to azoles and echinocandins, respectively. Studies from Northern Europe and the USA reported a high number of cases caused by C. glabrata and a low number of cases caused by C. parapsilosis. In contrast, reports from Spain and Brazil demonstrated a lower number of cases caused by C. glabrata and higher number of cases attributed to C. parapsilosis. The explanation for this finding is unknown, although it may be a consequence of the impact of climate, antifungal policy, or central venous catheter care procedures. Compiled data from the ARTEMIS DISK registry are useful when studying temporal changes in the frequency of invasive Candida spp isolates in large geographic areas from 1997 to 2007 [16,27,28] (Fig. 2). C. albicans remained the most frequent species worldwide, although this frequency was decreasing. The frequency of C. glabrata and C. krusei was stable, although an increase in the frequency of C. parapsilosis and C. tropicalis was reported. Influence of the Patient s Predisposing Conditions The kind of patient also has a considerable influence on the distribution and frequency of Candida spp., regardless of the geographic area. Malignancies and surgery are common predisposing factors for the development of candidemia, which is more frequent at age extremes. In addition, patients commonly carry central venous catheters and have received broad-spectrum antibiotics [10,21]. The differences in incidence between adults and children are also reflected in the species distribution. C. albicans is 100% 80% 60% C. albicans C. glabrata C. parapsilosis C. tropicalis C. krusei Other % % 0% FIG. 2. Data compiled from the ARTEMIS DISK registry on the temporal change in species distribution among invasive Candida isolates from 1997 to 2007.
4 8 Clinical Microbiology and Infection, Volume 20 Supplement 6, June 2014 CMI more frequent in patients aged up to 18 years. Interestingly, the frequency of C. parapsilosis decreases with age, whereas C. glabrata is more common in the elderly [29,30]. Differences have also been detected between neonates and adult patients: C. albicans and C. parapsilosis are more frequent in neonates (60% vs. 50% and 24% vs. 12%, respectively) [30]. Both species usually cause catheter-related candidemia, and catheters are widely used in neonates [10]. In contrast, the frequency of cases caused by azole-resistant species such as C. glabrata and C. krusei is much lower in neonates (3% vs. 23% and 0% vs. 2%), probably reflecting scant use of azoles in neonatology [30]. A recent study of children in Spain showed the high percentage of cases of candidemia caused by C. parapsilosis (47%), which even exceeded that of C. albicans (37%) [31]. Species distribution is highly dependent on the patient s underlying condition. C. glabrata is the most frequently detected species in stem cell recipients; C. krusei is also relevant in these patients, probably owing to the widespread use of azoles in this setting, which may promote infection by these two azole-resistant species. However, other patients, such as solid organ recipients, are infected mainly by C. albicans and C. glabrata [32 34]. A considerable number of episodes of candidemia are diagnosed in the intensive care unit (ICU) [21,35]. Comparison of patients admitted to the ICU with those admitted to other wards reveals no considerable variations in species distribution [35,36], probably because the species found in the ICU reflect those found in the rest of the hospital [37]. Finally, the use of antifungal agents also has an impact on the distribution of Candida spp., as shown in a study reporting a large number of patients collected from all over France [38]. Recent exposure to fluconazole or caspofungin affected the distribution of Candida spp. by promoting infection by C. glabrata and C. krusei (use of fluconazole) and infection by C. parapsilosis, C. glabrata, and C. krusei (use of caspofungin). Influence of Local Hospital Epidemiology Candida infections can be caused by strains of the patient s own microbiota [39,40]. The use of broad-spectrum antibiotics leads to overgrowth of Candida spp. in the gastrointestinal tract. Microorganisms can reach the bloodstream by translocation and cause candidemia, which is common in patients with mucositis or after disruption of the skin as a result of colonization. However, patients can also become infected by exogenous isolates that are not part of their own microbiota. Exogenous isolates can colonize the skin, intravenous catheters, and parenteral infusions and they are often involved in outbreaks where several patients become infected by the same isolate [41]. Horizontal transmission of exogenous isolates between patients admitted to the hospital increases the frequency of Candida spp. and, therefore, the frequency of invasive disease. Most reported outbreaks of candidemia involved patients from the adult medical and post-surgical ICU, patients from oncology haematology units, and neonates [41]. This finding probably reflects not only the high number of episodes of candidemia diagnosed in the units, but also the characteristics of these patients [7,42 47]. Relatively recent reports on outbreaks of infections caused by C. parapsilosis show that patients mainly had candidemia and were admitted to ICUs. Patients were both adult and paediatric, although neonates were also frequently involved. Typing of isolates from the patients involved and from the environment (including health care personnel) showed that genotypes from patients were commonly found on the hands of the health care workers, which are a common source of exogenous isolates [42,45,46,48 51]. Patients skin or central venous catheters can become infected by exogenous isolates after manipulation of medical devices by health care workers, particularly in the adult and neonatal ICU. Neonates and adult patients are also infected by C. albicans. Again, health care workers play a key role in transmission, and artificial nails have been reported to be a possible source of isolates causing an outbreak [52,53]. In a neonatal ICU, the first patient involved in an outbreak acquired the infection during delivery, and the isolate was transmitted to the other two patients during admission to the unit [54]. We recently typed 217 C. albicans isolates from 202 patients with candidemia admitted to the hospital during a 5-year period. We found 19 genotypes (11% of the total) that were epidemic and infected two or more patients. Clusters involved 2 6 patients each, and up to 25% of patients were infected by epidemic genotypes found in at least one other patient [55]. The same approach was adopted with C. parapsilosis isolates. We found 78 genotypes, of which 18% were epidemic and involved 14 clusters [56]. Epidemic genotypes were mostly detected in neonatology, suggesting more active horizontal transmission of these pathogens in both units. The higher frequency of nosocomial transmission may explain the higher frequency of these two species in neonates than in adult patients [30]. In conclusion, differences in the distribution of Candida spp can be found between geographical regions. However, underlying condition and antifungal agents received have a considerable effect on local epidemiology. The fact that C. albicans and C. parapsilosis are transmitted effectively from patient to patient may contribute to the high number of cases of candidemia caused by these two species.
5 CMI Guinea Global trends in Candida species distribution 9 Acknowledgements We would like to thank Thomas O Boyle for editing and proofreading the article. This study was presented in part at the 2nd ESCMID Conference on Invasive Fungal Infections, Rome, Italy, 16 18th January This work was supported by grants from Fondo de Investigacion Sanitaria (grants number PI11/00167). J. Guinea (MS09/00055) is supported by the Fondo de Investigacion Sanitaria. Transparency Declaration This study does not present any conflicts of interest for its authors. References 1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through N Engl J Med 2003; 348: Lepak A, Andes D. Fungal sepsis: optimizing antifungal therapy in the critical care setting. Crit Care Clin 2011; 27: Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. The PATH (prospective antifungal therapy) ALLIANCE ( â ) registry and invasive fungal infections: update Diagn Microbiol Infect Dis 2012; 73: Neofytos D, Lu K, Hatfield-Seung A et al. Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy. Diagn Microbiol Infect Dis 2013; 75: Montagna MT, Caggiano G, Lovero G et al. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA project). Infection 2013; 41: Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco bay area, : results of population-based laboratory active surveillance. Clin Infect Dis 1998; 27: Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis 1993; 17: Colombo AL, Nucci M, Park BJ et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006; 44: Puig-Asensio M, Padilla B, Garnacho-Montero J et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect 2013; doi: / Pappas PG, Rex JH, Lee J et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: Fridkin SK. Candidemia is costly plain and simple. Clin Infect Dis 2005; 41: Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: Pfaller MA, Diekema DJ, Rinaldi MG et al. Results from the ARTEMIS DISK global antifungal surveillance study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. JClinMicrobiol2005; 43: Kao AS, Brandt ME, Pruitt WR et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999; 29: Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002; 40: Poikonen E, Lyytikainen O, Anttila VJ, Ruutu P. Candidemia in Finland, Emerg Infect Dis 2003; 9: Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: Almirante B, Rodrıguez D, Park BJ et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to J Clin Microbiol 2005; 43: Arendrup MC, Fuursted K, Gahrn-Hansen B et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 2005; 43: Arendrup MC, Bruun B, Christensen JJ et al. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol 2011; 49: Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsaker T, Gaustad P. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 2006; 44: Lockhart SR, Iqbal N, Ahlquist AM et al. Species identification and antifungal susceptibility of Candida bloodstream isolates from population-based surveillance in two US cities: J Clin Microbiol 2012; 50: Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to J Clin Microbiol 2013; 51: Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007; 45: Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the artemis disk global antifungal surveillance study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48: Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002; 40: Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: sentry antimicrobial surveillance program, 1997 to J Clin Microbiol 2002; 40: Peman J, Canton E, Linares-Sicilia MJ et al. Epidemiology and antifungal susceptibility of bloodstream fungal isolates in pediatric patients: a
6 10 Clinical Microbiology and Infection, Volume 20 Supplement 6, June 2014 CMI Spanish multicenter prospective survey. J Clin Microbiol 2011; 49: Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter prospective antifungal therapy (PATH) ALLIANCE registry. Clin Infect Dis 2009; 48: Neofytos D, Fishman JA, Horn D et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12: Pappas PG, Alexander BD, Andes DR et al. Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (TRANSNET). Clin Infect Dis 2010; 50: Peman J, Canton E, Quindos G et al. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother 2012; 67: Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-icu settings in the SENTRY antimicrobial surveillance program ( ). Int J Antimicrob Agents 2011; 38: Leroy O, Gangneux JP, Montravers P et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France ( ). Crit Care Med 2009; 37: Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011; 55: Charles PE, Dalle F, Aube H et al. Candida spp. Colonization significance in critically ill medical patients: a prospective study. Intensive Care Med 2005; 31: Miranda LN, van der Heijden IM, Costa SF et al. Candida colonisation as a source for candidaemia. J Hosp Infect 2009; 72: Marcos-Zambrano LJ, Escribano P, Bouza E, Guinea J. Use of molecular typing tools for the study of hospital outbreaks of candidemia. Rev Iberoam Micol 2013; Dizbay M, Kalkanci A, Sezer BE et al. Molecular investigation of a fungemia outbreak due to Candida parapsilosis in an intensive care unit. Braz J Infect Dis 2008; 12: Barchiesi F, Caggiano G, Falconi Di Francesco L, Montagna MT, Barbuti S, Scalise G. Outbreak of fungemia due to Candida parapsilosis in a pediatric oncology unit. Diagn Microbiol Infect Dis 2004; 49: Asmundsdottir LR, Erlendsdottir H, Haraldsson G, Guo H, Xu J, Gottfredsson M. Molecular epidemiology of candidemia: evidence of clusters of smoldering nosocomial infections. Clin Infect Dis 2008; 47: e17 e Kuhn DM, Mikherjee PK, Clark TA et al. Candida parapsilosis characterization in an outbreak setting. Emerg Infect Dis 2004; 10: Posteraro B, Bruno S, Boccia S et al. Candida parapsilosis bloodstream infection in pediatric oncology patients: results of an epidemiologic investigation. Infect Control Hosp Epidemiol 2004; 25: Cugno C, Cesaro S. Epidemiology, risk factors and therapy of candidemia in pediatric hematological patients. Pediatr Rep 2012; 4: e Diekema DJ, Messer SA, Hollis RJ, Wenzel RP, Pfaller MA. An outbreak of Candida parapsilosis prosthetic valve endocarditis. Diagn Microbiol Infect Dis 1997; 29: Clark TA, Slavinski SA, Morgan J et al. Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol 2004; 42: Reissa E, Lasker BA, Iqbal NJ, James MJ, Arthington-Skaggs BA. Molecular epidemiology of Candida parapsilosis sepsis from outbreak investigations in neonatal intensive care units. Infect Genet Evol 2008; 8: Hernandez-Castro R, Arroyo-Escalante S, Carrillo-Casas EM et al. Outbreak of Candida parapsilosis in a neonatal intensive care unit: a health care workers source. Eur J Pediatr 2010; 169: Parry MF, Grant B, Yukna M et al. Candida osteomyelitis and diskitis after spinal surgery: an outbreak that implicates artificial nail use. Clin Infect Dis 2001; 32: Boccia S, Posteraro B, La Sorda M et al. Genotypic analysis by 27a DNA fingerprinting of Candida albicans strains isolated during an outbreak in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2002; 23: Tiraboschi IN, Carnovale S, Benetucci A et al. Candida albicans outbreak in a neonatal intensive care unit. Rev Iberoam Micol 2007; 24: Escribano P, Rodrıguez-Creixems M, Sanchez-Carrillo C, Mu~noz P, Bouza E, Guinea J. Endemic genotypes of Candida albicans causing fungemia are frequent in the hospital. J Clin Microbiol 2013; 51: Escribano P, Marcos-Zambrano LJ, Recio S et al. Genotypic analysis of Candida parapsilosis isolates causing fungemia: Evidence of endemic genotypes in the hospital. 23rd European Congress of Clinical Microbiology and Infectious Diseases, abstract (R-2708) 2013.
MixInYest: a multicenter survey on mixed yeast infections in Europa
MixInYest: a multicenter survey on mixed yeast infections in Europa COORDINATORS: - Ana Alastruey-Izquierdo, Mycology Reference Laboratory, National Centre for Microbiology, Spain - Cornelia Lass-Flörl,
More informationFungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline
More informationCandida tropicalis fungaemia: incidence, risk factors and mortality in a general hospital
ORIGINAL ARTICLE MYCOLOGY Candida tropicalis fungaemia: incidence, risk factors and mortality in a general hospital P. Muñoz, M. Giannella, C. Fanciulli, J. Guinea, M. Valerio, L. Rojas, M. Rodríguez-Créixems
More informationEpidemiology of candidemia in intensive care units
International Journal of Antimicrobial Agents 32 Suppl. 2 (2008) S87 S91 www.ischemo.org Epidemiology of candidemia in intensive care units Emilio Bouza*, Patricia Muñoz Servicio de Microbiología Clínica
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01268.x Secular trends in nosocomial candidaemia in non-neutropenic patients in an Italian tertiary hospital R. Luzzati 1,2, B. Allegranzi 1, L. Antozzi 1, L.
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationReceived 4 August 2010/Returned for modification 23 October 2010/Accepted 19 November 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2011, p. 561 566 Vol. 55, No. 2 0066-4804/11/$12.00 doi:10.1128/aac.01079-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Candida
More informationFKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Clinical Infectious Diseases Advance Access published July 9, 2014 MAJOR ARTICLE FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia Nicholas D. Beyda, 1 Julie John, 1 Abdullah
More informationAntifungal Susceptibility of Bloodstream Candida Isolates in Pediatric Patients
ISSN: 2319-7706 Volume 4 Number 3 (2015) pp. 716-720 http://www.ijcmas.com Original Research Article Antifungal Susceptibility of Bloodstream Candida Isolates in Pediatric Patients Deepak Kumar 1, Sayan
More informationCandida glabrata: an emerging pathogen in Brazilian tertiary care hospitals
Medical Mycology January 2013, 51, 38 44 Candida glabrata: an emerging pathogen in Brazilian tertiary care hospitals ARNALDO L. COLOMBO *, MARCIA GARNICA, LUIS FERNANDO ARANHA CAMARGO, CLOVIS ARNS DA CUNHA,
More informationRapid Antifungal Susceptibility Determination for Yeast Isolates by Use of Etest Performed Directly on Blood Samples from Patients with Fungemia
JOURNAL OF CLINICAL MICROBIOLOGY, June 2010, p. 2205 2212 Vol. 48, No. 6 0095-1137/10/$12.00 doi:10.1128/jcm.02321-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Rapid Antifungal
More informationThis is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Clinical Medicine Insights: Therapeutics Original Research Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Impact of the New Clinical Breaking Points Proposed
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationCandidemia in Norway (1991 to 2003): Results from a Nationwide Study
JOURNAL OF CLINICAL MICROBIOLOGY, June 2006, p. 1977 1981 Vol. 44, No. 6 0095-1137/06/$08.00 0 doi:10.1128/jcm.00029-06 Copyright 2006, American Society for Microbiology. All Rights Reserved. Candidemia
More informationNationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationTitle: Author: Speciality / Division: Directorate:
Antifungal guidelines for CANDIDIASIS INFECTIONS (Adults) Proven infection: Targeted antifungal therapy should be prescribed for: o Positive cultures from a sterile site with clinical or radiological abnormality
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationon December 11, 2018 by guest
JCM Accepts, published online ahead of print on 12 December 2012 J. Clin. Microbiol. doi:10.1128/jcm.03125-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Biographical Feature;
More informationThe incidence of invasive fungal infections
AN EPIDEMIOLOGIC UPDATE ON INVASIVE FUNGAL INFECTIONS * Michael A. Pfaller, MD ABSTRACT *Based on a presentation given by Dr Pfaller at a symposium held in conjunction with the 43rd Interscience Conference
More informationVoriconazole Rationale for the EUCAST clinical breakpoints, version March 2010
Voriconazole Rationale for the EUCAST clinical breakpoints, version 2.0 20 March 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationReceived 12 December 2010/Returned for modification 5 January 2011/Accepted 16 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1765 1771 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.02517-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multicenter
More informationAmphotericin B, antifungal susceptibility, bloodstream infections, Candida spp., posaconazole, sus-
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01310.x Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital A. Bedini 1, C. Venturelli 2, C. Mussini 1, G.
More informationINFEZIONI FUNGINE E PERCORSI TERAPEUTICI IN ICU. Claudio Viscoli Professor of Infectious Disease University of Genoa
INFEZIONI FUNGINE E PERCORSI TERAPEUTICI IN ICU Claudio Viscoli Professor of Infectious Disease University of Genoa What I would like to discuss with you today When to start an antifungal therapy (before
More informationCandida auris: an Emerging Hospital Infection
National Center for Emerging and Zoonotic Infectious Diseases Candida auris: an Emerging Hospital Infection Paige Armstrong MD MHS Epidemic Intelligence Service Officer Mycotic Diseases Branch Association
More informationReceived 31 March 2009/Returned for modification 26 May 2009/Accepted 22 June 2009
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2009, p. 2766 2771 Vol. 47, No. 9 0095-1137/09/$08.00 0 doi:10.1128/jcm.00654-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Comparison
More informationReceived 18 December 2008/Returned for modification 9 February 2009/Accepted 9 April 2009
JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p. 1942 1946 Vol. 47, No. 6 0095-1137/09/$08.00 0 doi:10.1128/jcm.02434-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Activity
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2007.01758.x Impact of early central venous catheter removal on outcome in patients with candidaemia D. Rodriguez 1, B. J. Park 2, B. Almirante 1, M. Cuenca-Estrella
More informationReceived 22 November 2007/Returned for modification 29 December 2007/Accepted 12 January 2008
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2008, p. 1396 1400 Vol. 52, No. 4 0066-4804/08/$08.00 0 doi:10.1128/aac.01512-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. In Vitro
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationVoriconazole. Voriconazole VRCZ ITCZ
7 7 8 7 8 fluconazole itraconazole in vitro in vivo Candida spp. C. glabrata C. krusei Cryptococcus neoformans in vitro Aspergillus spp. in vitro in vivo Aspergillus fumigatus Candida albicans C. krusei
More informationCurrent options of antifungal therapy in invasive candidiasis
Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida
More informationCandida albicans 426 (64.0 ) C. albicans non-albicans
74 2006 1) 2) 1) 3) 4) 5) 6) 1) 2) 3) 4) 5) 6) 17 9 26 18 3 8 2003 10 2004 3 6 9,083 666 (7.3 ) Candida albicans 426 (64.0 ) C. albicans non-albicans 233 (35.0 ) Non-albicans Candida glabrata Candida tropicalis
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationEpidemiology and Outcomes of Candidaemia among Adult Patients Admitted at Hospital Universiti Sains Malaysia (HUSM): A 5-Year Review
Epidemiology and Outcomes of Candidaemia among Adult Patients Admitted at Hospital Universiti Sains Malaysia (HUSM): A 5-Year Review Haydar A a a Department of Internal Medicine, Kulliyyah of Medicine,
More informationTable 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.
AUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA 2008-2011 Part 1: The Yeasts In this article, an update of recent changes to the CLSI antifungal standards for susceptibility testing of yeasts is presented. We
More informationDistribution and epidemiology of Candida species causing fungemia at a Saudi Arabian hospital,
International Journal of Infectious Diseases (2007) 11, 239 244 http://intl.elsevierhealth.com/journals/ijid Distribution and epidemiology of Candida species causing fungemia at a Saudi Arabian hospital,
More informationRisk Factors for Mortality in Patients with Candidemia and the Usefulness of a Candida Score
Korean J Med Mycol 18(3), 2013 Original Article Risk Factors for Mortality in Patients with Candidemia and the Usefulness of a Candida Score In Ki Moon, Eun Jung Lee, Hyo Chul Kang, Shi Nae Yu, Jee Wan
More informationOutcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei
J Antimicrob Chemother 211; 66: 375 3 doi:1.193/jac/dkq446 Advance Access publication 8 December 21 Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata
More informationNationwide study of candidemia, antifungal use and antifungal drug. resistance in Iceland,
JCM Accepts, published online ahead of print on 26 December 2012 J. Clin. Microbiol. doi:10.1128/jcm.02566-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Nationwide study
More informationNosocomial Candidemia in intensive care units of a tertiary care hospital, New Delhi, India
ISSN: 2319-7706 Volume 3 Number 6 (2014) pp. 513-517 http://www.ijcmas.com Original Research Article Nosocomial Candidemia in intensive care units of a tertiary care hospital, New Delhi, India Priyanka
More informationReducing the antifungal drugs consumption in the ICU
Reducing the antifungal drugs consumption in the ICU Philippe Montravers Département d Anesthésie et Réanimation Chirurgicale CHU Bichat Claude Bernard Pole TCAUR, HUPNVS Assistance Publique-Hôpitaux de
More informationAntifungal Stewardship. Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul
Antifungal Stewardship Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul 1 2 Objectives What do we know? Invasive Candida and Aspergillosis Impact
More informationSeminational Surveillance of Fungemia in Denmark: Notably High Rates of Fungemia and Numbers of Isolates with Reduced Azole Susceptibility
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2005, p. 4434 4440 Vol. 43, No. 9 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.9.4434 4440.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationEvaluation of the predictive indices for candidemia in an adult intensive care unit
Revista da Sociedade Brasileira de Medicina Tropical 48(1):77-82, Jan-Feb, 2015 http://dx.doi.org/10.1590/0037-8682-0292-2014 Major Article Evaluation of the predictive indices for candidemia in an adult
More informationInterpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing
CLINICAL MICROBIOLOGY REVIEWS, Apr. 2006, p. 435 447 Vol. 19, No. 2 0893-8512/06/$08.00 0 doi:10.1128/cmr.19.2.435 447.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Interpretive
More informationWHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU?
WHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU? Empiric antifungal therapy should be considered in critically ill patients with risk factors
More informationReceived 12 May 2009/Returned for modification 18 July 2009/Accepted 29 July 2009
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 2009, p. 3185 3190 Vol. 47, No. 10 0095-1137/09/$08.00 0 doi:10.1128/jcm.00946-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Variation
More informationCase Studies in Fungal Infections and Antifungal Therapy
Case Studies in Fungal Infections and Antifungal Therapy Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017 Disclosures No financial disclosures or industry
More information1* 1. Vijaya S. Rajmane, Shivaji T. Mohite
ISSN 2231-4261 ORIGINAL ARTICLE Comparison of the VITEK 2 Yeast Antifungal Susceptibility ing with CLSI Broth Microdilution Reference for ing Four Antifungal Drugs against Candida species Isolated from
More informationEvolution and aetiological shift of catheter-related bloodstream infection in a whole institution: the microbiology department may act as a watchtower
ORIGINAL ARTICLE EPIDEMIOLOGY Evolution and aetiological shift of catheter-related bloodstream infection in a whole institution: the microbiology department may act as a watchtower M. Rodríguez-Créixems
More informationBSI. Candida auris: A globally emerging multidrug-resistant yeast 5/19/2017. First report of C. auris from Japan in 2009
5/9/7 BSI Candida auris: A globally emerging multidrug-resistant yeast Mycotic Diseases Branch DFWED Friday Seminar August 6, 6 National Center for Emerging and Zoonotic Infectious Diseases Division of
More informationReceived 13 September 2006/Returned for modification 6 November 2006/Accepted 26 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 858 864 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01900-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Correlation
More informationIsolates from a Phase 3 Clinical Trial. of Medicine and College of Public Health, Iowa City, Iowa 52242, Wayne, Pennsylvania ,
JCM Accepts, published online ahead of print on 26 May 2010 J. Clin. Microbiol. doi:10.1128/jcm.00806-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationObjec&ves. Clinical Presenta&on
Michelle A. Barron, MD Associate Professor of Medicine Division of Infectious Diseases University of Colorado Denver Objec&ves Determine who is at risk for invasive candidiasis. Understand whether prophylaxis
More informationCandidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex
Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex ORIGINAL ARTICLE ABSTRACT Introduction: Although the spectrum of fungi causing bloodstream fungal infections
More informationEchinocandin Susceptibility Testing of Candida Isolates Collected during a 1-Year Period in Sweden
JOURNAL OF CLINICAL MICROBIOLOGY, July 2011, p. 2516 2521 Vol. 49, No. 7 0095-1137/11/$12.00 doi:10.1128/jcm.00201-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Echinocandin
More informationReceived 21 July 2008/Accepted 3 September 2008
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2008, p. 3585 3590 Vol. 46, No. 11 0095-1137/08/$08.00 0 doi:10.1128/jcm.01391-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Validation
More informationNosocomial Candidemia; Risk Factors and Prognosis Revisited; 11 Years Experience from a Norwegian Secondary Hospital
Nosocomial Candidemia; Risk Factors and Prognosis Revisited; 11 Years Experience from a Norwegian Secondary Hospital Jan-Erik Berdal 1 *, Rolf Haagensen 2, Trond Ranheim 3, Jørgen V. Bjørnholt 4 1 Department
More informationEfficacy of a Novel Echinocandin, CD101, in a Mouse Model of Azole-Resistant Disseminated Candidiasis
Efficacy of a Novel Echinocandin, CD0, in a Mouse Model of Azole-Resistant Disseminated Candidiasis L. Miesel, K-Y Lin, J. C. Chien, M. L. Hsieh, V. Ong, and K. Bartizal Eurofins Panlabs, Taipei, Taiwan
More informationReceived 29 October 2009/Returned for modification 4 January 2010/Accepted 9 February 2010
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2010, p. 1366 1377 Vol. 48, No. 4 0095-1137/10/$12.00 doi:10.1128/jcm.02117-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Results from
More informationSpecies Distribution and Antifungal Drug Susceptibility of Candida in Clinical Isolates from a Tertiary Care Centre at Bareilly
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 1 Ver. II (January. 2017), PP 57-61 www.iosrjournals.org Species Distribution and Antifungal
More information9/7/2018. Faculty. Overcoming Challenges in the Management of Invasive Fungal Infections. Learning Objectives. Faculty Disclosure
Faculty Overcoming Challenges in the Management of Invasive Fungal James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Departments of Pharmacy and Infectious
More informationEpidemiological Study on Candida Species in Patients with Cancer in the Intensive Care Unit
ORIGINAL ARTICLE Public Health Res Perspect 2017;8(6):384 388 eissn 2233-6052 Epidemiological Study on Candida Species in Patients with Cancer in the Intensive Care Unit Young-ju Choi a, Byeongyeo Lee
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationAntifungal Treatment in Neonates
Antifungal Treatment in Neonates Irja Lutsar University of Tartu, Estonia Lisbon, 12. October 2015 Prevalence of invasive fungal infections in NeoINN database 2005-2014 UK; 2012-2014 Estonia & Greece 1
More informationEvidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections. Presenter. Disclosures
Evidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections Presenter James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University
More informationDr Eggimann collaborated in several industrysponsored. clinical trials since Talk ID: year old BMI 41 Transferred for septic shock
Suggestions to prevent Candida infections Dr Philippe Eggimann, PD&MER Service de Médecine Intensive Adulte www.soins-intensifs.chuv.ch Anything I say can be highly biased Dr Eggimann collaborated in several
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationCatheter-related bloodstream infection caused by Enterococcus spp.
ORIGINAL ARTICLE BACTERIOLOGY Catheter-related bloodstream infection caused by Enterococcus spp. E. Reigadas 1, M. Rodríguez-Créixems 1,2,3, M. Guembe 1,C.Sánchez-Carrillo 1, P. Martín-Rabadán 1,2 and
More informationAnidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies
Received: 1 February 2017 Revised: 11 May 2017 Accepted: 11 May 2017 DOI: 10.1111/myc.12641 ORIGINAL ARTICLE Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationSpecies distribution and antifungal susceptibility of bloodstream fungal isolates in paediatric patients in Mexico: a nationwide surveillance study
J Antimicrob Chemother 2013; 68: 2847 2851 doi:10.1093/jac/dkt283 Advance Access publication 18 July 2013 Species distribution and antifungal susceptibility of bloodstream fungal isolates in paediatric
More informationCandiduria in ICU : when and how to treat? Dr. Debashis Dhar Dept of Critical Care and Emergency Medicine Sir Ganga Ram Hospital
Candiduria in ICU : when and how to treat? Dr. Debashis Dhar Dept of Critical Care and Emergency Medicine Sir Ganga Ram Hospital Introduction Nosocomial bacteriuria or candiduria develops in up to 25%
More informationEvaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed
J Antimicrob Chemother 2014; 69: 1993 1999 doi:10.1093/jac/dku053 Advance Access publication 21 March 2014 Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed
More informationReceived 25 September 2006/Returned for modification 4 December 2006/Accepted 26 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 796 802 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01986-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Multicenter
More informationEarly Diagnosis and Therapy for Fungal Infections
Early Diagnosis and Therapy for Fungal Infections Debra Goff PharmD, FCCP Clinical Associate Professor Infectious Disease Specialist The Ohio State University Medical Center Columbus Ohio, USA The Ohio
More informationon March 29, 2019 by guest
JCM Accepts, published online ahead of print on 4 May 2011 J. Clin. Microbiol. doi:10.1128/jcm.00201-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationSpecies distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002
Fluconazole J Microbiol Immunol susceptibility Infect of Candida 2004;37:236-241 Species distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002 Jiun-Ling Wang
More informationFungal Infection in the ICU: Current Controversies
Fungal Infection in the ICU: Current Controversies Andrew F. Shorr, MD, MPH, FCCP, FACP Washington Hospital Center Georgetown University, Washington, DC Disclosures I have served as a consultant to, researcher/investigator
More information1 Guidelines for the Management of Candidaemia
1 Guidelines for the Management of Candidaemia LIVERPOOL CLINICAL LABORATORIES GUIDELINE FOR THE MANAGEMENT OF CANDIDAEMIA IN NON-NEUTROPENIC ADULT PATIENTS AND PROPHYLAXIS/PRE-EMPTIVE TREATMENT IN HIGH
More informationOriginal Articles. Introduction
Medical Mycology April 2013, 51, 225 230 Original Articles Is the incidence of candidemia caused by Candida glabrata increasing in Brazil? Five-year surveillance of Candida bloodstream infection in a university
More informationFrequency, Clinical Presentation and Microbiological Spectrum of Candidemiain a Tertiary Care Center in Karachi, Pakistan
281 ORIGINAL ARTICLE Frequency, Clinical Presentation and Microbiological Spectrum of Candidemiain a Tertiary Care Center in Karachi, Pakistan Sunil Kumar, 1 Kiran Kalam, 2 Sajjad Ali, 3 Sualleha Siddiqi,
More informationHistorical trends in the epidemiology of candidaemia: analysis of an 11-year period in a tertiary care hospital in Brazil
288 Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 108(2): 288-292, April 2013 Historical trends in the epidemiology of candidaemia: analysis of an 11-year period in a tertiary care hospital in Brazil Marcos
More informationItraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston
REVIEW Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston Division of Hematology-Oncology, Department of Medicine, UCLA Medical Center, Los
More informationReceived 26 July 2006/Returned for modification 10 October 2006/Accepted 16 October 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2007, p. 70 75 Vol. 45, No. 1 0095-1137/07/$08.00 0 doi:10.1128/jcm.01551-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Use of Fluconazole
More informationReceived 7 January 2006/Returned for modification 22 February 2006/Accepted 28 February 2006
JOURNAL OF CLINICAL MICROBIOLOGY, May 2006, p. 1681 1685 Vol. 44, No. 5 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.5.1681 1685.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved.
More informationConvegno Nazionale Terapia Antibiotica dei patogeni. Le candidemie oggi: una gestione articolata
Convegno Nazionale Terapia Antibiotica dei patogeni multiresistenti (MDRO): una sfida aperta Ferrara, 15 Giugno 2018 Le candidemie oggi: una gestione articolata Michele Bartoletti Infectious Diseases Unit
More informationInvasive candidiasis; a review article
Jundishapur Journal of Microbiology (2009); 2(1): 1-6 1 Review article Invasive candidiasis; a review article Majid Zarrin 1, Ali Zarei Mahmoudabadi 1,2 1 Department of Medical Mycoparasitology, School
More informationAbstract. Introduction. Editor: E. Roilides
ORIGINAL ARTICLE MYCOLOGY Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme M. C. Arendrup
More informationCandidemia: New Sentinel Surveillance in the 7-County Metro
Candidemia: New Sentinel Surveillance in the 7-County Metro Brittany VonBank, MPH Paula Vagnone, MT (ASCP) 651-201-5414 www.health.state.mn.us Health Care-associated Infections & Antimicrobial Resistance
More informationAntifungal drug resistance among Candida species: mechanisms and clinical impact
mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Supplement article Antifungal drug resistance among Candida species: mechanisms and clinical impact Maurizio Sanguinetti, 1 Brunella Posteraro
More informationDiagnostic Issues, Clinical Characteristics, and Outcomes for Patients with Fungemia
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2011, p. 3300 3308 Vol. 49, No. 9 0095-1137/11/$12.00 doi:10.1128/jcm.00179-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Diagnostic
More informationLa terapia empirica nelle infezioni micotiche
La terapia empirica nelle infezioni micotiche Spinello Antinori Dipartimento di Scienze Biomediche e Cliniche Luigi Sacco Castellanza, 5 ottobre 2013 Empiric antifungal therapy: definition The receipt
More informationAntifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences
5th MMTN Conference 5-6 November 2016 Bangkok, Thailand 10:20-10:45, 6 Nov, 2016 Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences Yee-Chun Chen, M.D., PhD. Department of Medicine,
More informationCandidaemia Observed at a University Hospital in Milan (Northern Italy) and Review of Published Studies from 2010 to 2014
DOI 10.1007/s11046-014-9786-9 Candidaemia Observed at a University Hospital in Milan (Northern Italy) and Review of Published Studies from 2010 to 2014 Laura Milazzo Anna Maria Peri Cristina Mazzali Romualdo
More information